DCM
ATRA icon

Driehaus Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Driehaus Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-23,598
Closed -$873K – 385
2023
Q3 		$873K Buy
+23,598
New +$1.05M 0.01% 331
2019
Q2 		– Sell
-7,738
Closed -$7.69M – 467
2019
Q1 		$7.69M Sell
7,738
-1,139
-13% -$1.06M 0.29% 98
2018
Q4 		$7.71M Sell
8,877
-761
-8% -$707K 0.33% 86
2018
Q3 		$9.96M Sell
9,638
-1,516
-14% -$1.48M 0.31% 104
2018
Q2 		$10.2M Buy
11,154
+5,441
+95% +$5.84M 0.35% 90
2018
Q1 		$5.57M Buy
+5,713
New +$5.21M 0.2% 139

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Driehaus Capital Management's ATRA Position: Q4 2023 in Review

Driehaus Capital Management sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 23,598 shares — an estimated $873K sold.

Driehaus Capital Management first reported a position in ATRA in Q1 2018 and held it in 6 quarters. The position peaked at $10.2M in Q2 2018. 90 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • Driehaus Capital Management reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • Driehaus Capital Management sold 23,598 Atara Biotherapeutics shares in Q4 2023, an estimated $873K.
  • Driehaus Capital Management first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 6 quarters.
  • Driehaus Capital Management's Atara Biotherapeutics position peaked at $10.2M in Q2 2018.
  • 90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on Driehaus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.